John P. Hennessey

Director Técnico/Científico/I+D en NovaDigm Therapeutics, Inc. .

Health Technology

Perfil

John P.
Hennessey is currently the Chief Scientific Officer at NovaDigm Therapeutics, Inc. Prior to this, he worked as a Principal at Merck & Co., Inc.

Cargos activos de John P. Hennessey

Empresas	Cargo	Inicio
NovaDigm Therapeutics, Inc. NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.	Director Técnico/Científico/I+D	-

Todos los cargos activos de John P. Hennessey

Antiguos cargos conocidos de John P. Hennessey.

Empresas	Cargo	Fin
MERCK & CO., INC.	Corporate Officer/Principal	-

Ver el detalle de la experiencia de John P. Hennessey.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de John P. Hennessey.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
MERCK & CO., INC.	Health Technology

Empresas privadas	1
NovaDigm Therapeutics, Inc. NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.	Health Technology